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Abstract
Background: Expression of the two transcription factors microphthalmia-associated transcription factor (MITF) and
signal transducer and activator of transcription 3 (STAT3) are tightly connected to cell proliferation and survival,
and are important for melanocyte development. The co-regulation of MITF and STAT3 via their binding to a
common inhibitor Protein Inhibitor of Activated STAT3 (PIAS3) is intriguing. A better quantitative understanding of
this regulation is likely to be important for elucidation of the melanocyte biology.
Results: We present a mathematical model describing the MITF-PIAS3-STAT3 signalling network. A default
parameter set was developed, partly informed by the literature and partly by constraining the model to mimic
reported behavioural features of the system. In addition, a set of experiment-specific parameters was derived for
each of 28 experiments reported in the literature. The model seems capable of accounting for most of these
experiments in terms of observed temporal development of protein amounts and phosphorylation states. Further,
the results also suggest that this system possesses some regulatory features yet to be elucidated.
Conclusions: We find that the experimentally observed crosstalk between MITF and STAT3 via PIAS3 in
melanocytes is faithfully reproduced in our model, offering mechanistic explanations for this behaviour, as well as
providing a scaffold for further studies of MITF signalling in melanoma.
Background
The melanocytes are skin cells of neural crest origin that
constitute 5% - 20% of the basal layer of human epider-
mis [1-6]. The cell type is responsible for the melanin
pigment production and thus the colour patterning of
skin and hair in mammals. Melanoma, a cancer originat-
ing in melanocytes, is in its later stages notoriously
resistant to treatment, and although good prognostic
markers exist, the understanding of the underlying biol-
ogy is only slowly forthcoming [7]. While knowledge
about each single protein and gene involved in melano-
cyte development and regulation of homeostasis is
important, developing an understanding of the signalling
networks connecting the receptors on the surface to the
regulating effect on gene transcription in the nucleus
appears crucial in implementing efficient molecular
treatment strategies in the dawning era of personalized
cancer therapy.
Expression of microphthalmia-associated transcription
factor (MITF), the signal transducer and activator of
transcription 3 (STAT3), and their co-regulation via
protein inhibitor of activated STAT3 (PIAS3), are all
tightly connected to cell differentiation, proliferation
and survival. MITF is considered to be a master regula-
tory gene for melanocytes, and has been shown to play
important roles in the regulation of genes involved in
cell cycle progression, including Bcl-2 and CDK2 [8-10].
MITF is also of clinical significance, as MITF mutations
in humans cause Waardenburg syndrome type II [11],
and a significant number of malignant melanomas har-
bour MITF amplifications. MITF has also been pro-
posed to be important for both differentiation of
melanocytes and for tumour transformation [12]. MITF
has two phosphorylation sites influencing the PIAS3
binding: S73 and S409. These sites are phosphorylated
by different kinases in the MAPK pathway, the ERK and
RSK, respectively [13,14].
* Correspondence: joset@umb.no
1Centre for Integrative Genetics (CIGENE), Department of Mathematical
Sciences and Technology, Norwegian University of Life Sciences, 1430 Ås,
Norway
Full list of author information is available at the end of the article
Thingnes et al. BMC Systems Biology 2012, 6:11
http://www.biomedcentral.com/1752-0509/6/11
© 2012 Thingnes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
STAT3 is a transcription factor involved in signal
transduction pathways that are activated by several
extracellular stimuli, including the IL-6 family of cyto-
kines. It is tyrosine phosphorylated by the Janus kinase
(JAK) or SRC. The resulting signal mediates cell growth,
differentiation, and survival [15-17]. The underlying
molecular details have only partly been elucidated [18].
PIAS3 has been identified as an inhibitor of both acti-
vated STAT3 and MITF [19-23]. PIAS3 can bind acti-
vated STAT3, as well as non-activated MITF in one of
its two inactive complexes. The phosphorylation of
MITF at S409 results in MITF dissociation from the
complex, and more PIAS3 is thereby made available. As
a result, more STAT3 is bound in complex with PIAS3
and is thus prevented from binding DNA and activating
target genes [22,24,25]. Similarly, expression of constitu-
tively active STAT3 will complex with unbound PIAS3,
resulting in less PIAS3 being available for binding to
MITF. Consequently, more active MITF is observed
[22].
The connection between MITF, STAT3 and PIAS3
(Figure 1) has several interesting features: (1) MITF and
STAT3 interacts through binding and sequestration of
their common inhibitor PIAS3 [19-22], (2) PIAS3 binds
to phosphorylated (activated) STAT3, but disassociates
from activated MITF [20] which introduces an asymme-
try to the network, (3) MITF has two phosphorylation
sites interfering with PIAS3 binding, and all four result-
ing phosphorylation states have different binding affi-
nities to PIAS3 [20]. We have developed a mathematical
model to incorporate quantitative aspects of the system
in order to both test if the current conceptions of the
system can account for observed results, and to serve as
a framework for further studies of this module’s interac-
tion with other pathways. See Figure 2 for a graphical
representation of the model. This dynamic model of the
MITF-PIAS3-STAT3 system was designed to be simple,
while still being capable of reproducing the available
results. The inputs to the model are the activation
events of the two transcription factors MITF and PIAS3.
When MITF becomes phosphorylated at S73 and/or
S409, the affinity to PIAS3, the degradation rate and the
transcriptional activity are altered. On the other hand,
STAT3 has only one relevant phosphorylation site,
which is phosphorylated by JAK. When STAT3 becomes
phosphorylated, the affinity to PIAS3 and the transcrip-
tional activity is altered. As output, the activation levels
of the two transcription factors are monitored: For
STAT3, this implies the amount of phosphorylated pro-
tein, while for MITF it represents a complex feature of
the distribution of MITF among the four phosphoryla-
tion states.
Results
Constraining model behaviour and parameter domains
Default values for the set of core parameters common to
all experimental settings were obtained partly directly
from the literature and partly by fitting model behaviour
to available data. These core parameters describe degra-
dation rate, production rate, binding affinity, and phos-
phorylation and de-phosphorylation rate (Table 1). For
further details on the parameter value deduction, see
Methods. We next singled out a representative selection
consisting of 28 well-reported experiments addressing
various relevant aspects of the MITF-STAT3-PIAS3 sys-
tem (Table 2), and tested to what degree the model was
able to account for the available experimental data. For
each experiment, a set of experiment-specific para-
meters, such as the effect of transfection on production
rates or the activation level in growing cells, was specifi-
cally incorporated to reflect the experimental setup and
conditions. These parameters were specifically set for
each experiment. In those cases where the experiments
were replicates, the experiment-specific parameters were
given identical values. While keeping the core para-
meters at default values, we manually searched for
experiment specific parameter values that minimized the
distance between the simulation output and the
reported results of the focal lab-experiment. The experi-
ment-specific perturbations of the model are provided
in the Methods section. We found that we were able to
account reasonably well for 27 of the 28 experiments.
Only experiment #26 seems to be beyond explanatory
reach by our model framework.
Robustness of fit between model results and
experimental data
We next investigated how sensitive the obtained fit
between the experimental data and the model results
was with respect to variation in the core parameter
Figure 1 Overview of the modelled network. The two
transcription factors MITF and STAT3 are phosphorylated by the
MAPK-pathway and the JAK-STAT-pathway, respectively. PIAS3
inhibits their activity as transcription factors by binding and forming
inactive complexes. The abundance of one transcription factor can
sequester PIAS3 to depletion, and eliminate the inhibition of the
other transcription factor.
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Figure 2 Graphical representation of the model. The graphs are represented in Systems Biology Graphical Notation [51] as implemented in
CellDesigner [50] version 4.2. A: The diagram shows the different states of each protein (rounded rectangles) and the possible state transitions
(arrows). Catalysed transitions are depicted as lines from the catalyst to a circle at the state transition arrow. The model has two input nodes:
ERK and JAK (white nodes). ERK is phosphorylating RSK1 (grey nodes). ERK and RSK1 are phosphorylating MITF (red nodes) at S73 (blue lines)
and S409 (pink lines), respectively. MITF in different phosphorylation states combines (red lines) with PIAS3 (yellow nodes) forming complexes
(orange grouping nodes). On the other side, JAK phosphorylates STAT3 (blue nodes), which is going into complex with PIAS3 when activated
(green grouping node). The output nodes of the model are all the free MITF states and the phosphorylated STAT3. Communication between the
ERK-RSK-MITF pathway and the JAK-STAT pathway via the competitive binding to free PIAS3 is the topic of this work. B: Production and
degradation. The amounts of phosphorylated ERK and JAK are represented by constants. The total amount of RSK1 is constant while the
phosphorylation state is dynamically determined. The amounts of MITF, PIAS3 and STAT3 are dynamically determined by the production and
degradation of the proteins. The broken arrows from the genes (yellow rectangles) to the proteins represent production, while arrows from the
proteins to the degradation node (red filled empty set symbol) represent degradation. C: Ubiquitination of MITF. All S73 phosphorylated MITF
can be ubiquitin tagged, in which case it will eventually be degraded. The ubiquitination is catalysed by phosphorylated ERK.
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values, in the 27 successful cases examined. While keep-
ing the experiment-specific parameters unchanged, 106
sets of the core parameters were sampled uniformly on
a logarithmic scale from a hypercube centred at the
default parameter values and within the range 0.5-2.0×
of each default value. For all sampled parameter sets, we
simulated the 27 successful experiments in Table 2 and
recorded success or failure accordingly. By analysing the
30 × 106 parameter matrix and the corresponding 28 ×
106 result matrix we studied the sensitivity of the suc-
cess rate of each experiment to variation in a given
parameter by computing success rates in bins of sorted
parameter sets, and used the sum of absolute deviations
from the overall success rate to range the parameters
according to sensitivity (Figure 3). Each experiment
tested different features of the system, which is reflected
in the parameter sensitivity. Some experiments are sen-
sitive only to one parameter. For example experiment
#1, which investigated the temporal development of
ERK and RSK1 kinase activities, and experiment #14,
which investigated the transcriptional activity of the
MITF-S73D mutant in response to transfection of
PIAS3 were both sensitive to a single parameter, the
RSK1 phosphorylation rate constant kRp+ and the PIAS3
Table 1 List of core parameters
No Parameter Value Description
1 kMp73E+ 0.00015 MITF phosphorylation on S73, ERK dependent (Mol
-1min-1)
2 kMp73- 0.03 MITF de-phosphorylation on S73 (min
-1)
3 kMp73a+ 0.025 MITF auto-phosphorylation on S73 (min
-1)
4 kMp409+ 0.0001 MITF phosphorylation on S409 (Mol
-1min-1)
5 kMp409- 0.04 MITF de-phosphorylation on S409 (min
-1)
6 kMass 0.01 MITF/PIAS3 association (Mol
-1min-1)
7 kMdiss 1 MITF/PIAS3 dissociation (min
-1)
8 kMp73ass 0.03 MITFp79/PIAS3 association (Mol
-1min-1)
9 kMp73diss 0.5 MITFp79/PIAS3 dissociation (min
-1)
10 kMp409ass 0.0001 MITFp409/PIAS3 association (Mol
-1min-1)
11 kMp409diss 1 MITFp409/PIAS3 dissociation (min
-1)
12 kMppass 0.01 MITFpp/PIAS3 association (Mol
-1min-1)
13 kMppdiss 1 MITFpp/PIAS3 dissociation (min
-1)
14 kSp+ 0.0002 STAT3 phosphorylation (Mol
-1min-1)
15 kSp- 0.04 STAT3 de-phosphorylation (min
-1)
16 kSpass 0.005 STAT3p/PIAS3 association (Mol
-1min-1)
17 kSpdiss 0.2 STAT3p/PIAS3 dissociation (min
-1)
18 pMITF 1 MITF production (Mol min
-1)
19 gMITF 0.0012 MITF degradation (min-1)
20 gMITFp73 0.02 MITFp73 degradation (min-1)
21 gMITFp409 0.01 MITFp409 degradation (min-1)
22 PPLAS3 0.262 PIAS3 production (Mol min
-1)
23 gPLAS3 0.008 PIAS3 degradation (min-1)
24 PSTAT3 0.211 STAT3 production (Mol min
-1)
25 gSTAT3 0.002 STAT3 degradation (min-1)
26 kRp+ 0.0004 RSK1 phosphorylation (Mol
-1min-1)
27 kRp 0.04 RSK1 de-phosphorylation (min
-1)
28 ERKp 10 ERKp concentration (Mol)
29 JAKp 10 JAKp concentration (Mol)
30 Ku 0.0001 Ubiquitination (Mol
-1min-1)
The parameter names follow a naming convention. The rate constants for phosphorylation events is a k with a subscript starting with a protein specification (R:
RSK1, M:MITF or S:STAT3), followed by a specification of a phosphorylation site (p73, p409 for MITF and p for STAT3) and finalized with a ‘ + ‘ for phosphorylation
rate constants and ‘ - ‘ for de-phosphorylation rate constants. The association and dissociation rate constants is a k with a subscript starting with a protein
specification followed by a phosphorylation state specification, and finalized with ‘ ass ’ or ‘ diss ’ respectively. The name of the parameters denoting the
production or degradation rates start with a p or a g respectively, and ends with a specification of the protein (and eventually phosphor state). The two constants
ERKp and JAKp, represent the amounts of phosphorylated ERK and JAK, respectively. These are altered to emulate signalling through the respective pathways.
‘ku’ is the ubiquitination rate constant.
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production rate PPLAS3, respectively. On the other hand,
experiment #17, which investigated the MITF-PIAS3
association in response to activation, and experiment
#18, which investigated S409A mutated MITF-PIAS3
association in response to activation were both sensitive
to more than half the parameters. Further, it was
observed that the experiments that dealt only with
MITF and the MITF-PIAS3 connection, and not with
STAT3 (experiments #2 - #16), were only affected by
the parameters regarding MITF. On the other hand,
experiments #19 to #24 were sensitive only to perturba-
tions of the STAT3 phosphorylation and de-phosphory-
lation constants, as well as the level of phosphorylated
JAK. Notably, three parameters did not affect the results
of any experiment: kMp409ass, kMp409diss, and PMITF. In
addition, three parameters had only weak effects:
PSTAT3, gSTAT3and ku.
Interpretation and qualification of selected experiments
Most of the experiment-specific simulations suggest that
the main underlying biological mechanisms seem to be
captured by the model. As an example, the result of
experiment #25 is plotted alongside the original figure
from [22] in Figure 4. The temporal development for all
variables for all experiment simulations can be found in
Additional file 1 - simulationFigures.zip. In the follow-
ing, we consider only those experiments in need of
further interpretation and qualification.
In experiment #7, the MITF-PIAS3 association after
activation was investigated. BL6-B16 melanoma cells
Table 2 An overview of the biological experiments
Description Reference
1. Temporal development of ERK and RSK1 kinase activity [14]Figure 5B
2. Distribution between MITF phosphorylation before stimulation [14]Figure 1 and 2
3. Temporal development of MITF phosphorylation states after stimulation [14]Figure 1 and 2
4. Temporal development of MITF degradation [14]Figure 1 and 2
5. MITF activity in response to PIAS3 transfection [19]Figure 6
6. Amount of MITF-PIAS3 complex in response to activation [20] Figure 2A
7. Amount of MITF-PIAS3 complex in response to activation with transfected MITF and PIAS3 [20] Figure 2B
8. MITF activity in response to transfection of constitutively active RSK1 [20] Figure 3A
9. MITF activity in response to PIAS3 [20] Figure 3B, left, black
10. MITF activity in response to transfection of PIAS3 and active RSK1 [20] Figure 3B, left, grey
11. Activity of a MITF-S409A mutant in response to PIAS3 [20] Figure 3B, right,
black
12. Activity of a MITF-S409A mutant in response to transfection of PIAS3 and active RSK1 [20] Figure 3B, right,
grey
13. Activity of MITF in response to transfection of PIAS3 [20] Figure 6
14. Activity of MITF-S73D mutant in response to transfection of PIAS3 [20] Figure 6
15. Activity of MITF-S409D mutant in response to transfection of PIAS3 [20] Figure 6
16. Activity of MITF-S73/409D mutant in response to transfection of PIAS3 [20] Figure 6
17. MITF-PIAS3 association in response to activation [22] Figure 3A
18. S409A mutated MITF-PIAS3 association in response to activation [22] Figure 3A
19. STAT3 activity in response to activation [22] Figure 3B
20. STAT3 activity in response to activation with transfected PIAS3 [22] Figure 3B
21. STAT3 activity in response to activation with transfected PIAS3 and small amount of MITF [22] Figure 3B
22. STAT3 activity in response to activation with transfected PIAS3 and large amount of MITF [22] Figure 3B
23. STAT3 activity in response to activation with transfected PIAS3 and small amount of S-409A mutated MITF [22] Figure 3B
24. STAT3 activity in response to activation with transfected PIAS3 and large amount of S409A mutated MITF [22] Figure 3B
25. MITF activity in response to transfection of Y705F mutated STAT3 and STAT3-C [22] Figure 4B
26. MITF and STAT3 activity in response to activation compared between wild type and mutated MITF (unable to bind
PIAS3)
[22] Figure 6D and E
27. STAT3 activity in response to transfection of MITF or S409D MITF mutation [22] Figure 7C
28. MITF activity in response to transfection of STAT3-C [22] Figure 7D
The numbers assigned to each experiment in the table is used to identify the experiment throughout this paper. For each experiment the reference and the
figure number within the reference are provided.
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were co-transfected with MITF and PIAS3. After 48
hours, the cells were treated with tetradecanoyl phorbol
acetate (TPA) for 30 minutes. The amount of MITF-
PIAS3 complex was measured before, and after 10 and
30 minutes of TPA treatment (Figure 5A). Two different
interpretations of the two bands representing MITF
have been proposed. In all cases, the lower band is
considered as representing un-phosphorylated MITF,
while the upper band may represent all phosphorylated
states, or alternatively only S73 phosphorylated MITF
[14,26]. If we assume that the upper band corresponds
to all phosphorylated MITF-PIAS3 complexes (which is
in accordance with what is assumed about the bands
representing MITF in [14]), we can predict the temporal
Figure 3 Parameter sensitivity for all experiments. Sensitivity for all experiments to perturbations in each parameter after permutations to
remove clearly insensitive parameters (no parameters passed the permutation threshold for experiment #26) is shown. Colour indicates the
normalized sensitivity measure
si,j
max(si,j)
j
Each experiment is insensitive to perturbations in the dark blue parameters, while highly sensitive to
the brown parameters.
Figure 4 Simulations and lab results experiment #25. A: Reprint of figure 4B in [22] (License agreement number 2838800627526): NIH 3T3
cells were co-transfected with the luciferase reporter under the control of the mMCP6 promoter, MITF, PIAS3, and STAT3 mutants (STAT3-C and
Y705F-STAT3). B: Simulation of the same experiment (Experiment 25 in Table 2). The white bars in the reprint and the blue bars in the simulation
results represent the MITF activity in cells transfected with only STAT3, the grey bars in the reprint and the green bars in the simulation results
represent the MITF activity in cells transfected with STAT3 and MITF, and the black bars in the reprint and the red bars in the simulation results
represents the MITF activity in cells transfected with STAT3, MITF and PIAS3.
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development of the distribution among the different
phosphorylation states. In our simulations (Figure 5B),
the amount of un-phosphorylated MITF-PIAS3 complex
decreases rapidly, which is in accordance with the lower
band in Figure 5A. The sum of all the phosphorylated
states is high after 10 minutes, and is falling again after
30 min, which is in accordance with the higher band in
Figure 5I. The distribution among the phosphorylated
states can thus be viewed as a prediction. However, it
has been suggested that the upper band represents only
S73 phosphorylated MITF [26], which is also supported
by our model. The S73 phosphorylated complex is also
high after 10 minutes, and falls again after 30 minutes.
If this is the case, the temporal development of the
other phosphorylated complexes (MITF-PIAS3p409,
MITF-PIAS3pp) can be viewed as predictions of unde-
tected MITF-PIAS3 phosphorylation states.
In experiments #19 - 24, the transcriptional activity of
STAT3 was measured in NIH 3T3 fibroblasts that were
co-transfected with STAT3, PIAS3, and with different
doses (0.05 μg, 0.1 μg) of MITF (wild type [WT] or
S409A [MUT]). After 48 hours of incubation, the cells
were activated with IL6/IL6R for 6 h. Transcriptional
activity of STAT3 was measured, and the mean ± the
SEM of three experiments is shown in Figure 6A. The
simulations of these experiments, which were performed
with equal experiment-specific parameters, captured the
reported results well (Figure 6B). However, there is a
striking, but un-noticed result both in the lab experi-
ment and the simulation in that there is no effect of
adding the smaller amount of wtMITF, while there is a
rather big effect of adding the greater amount of
wtMITF. Because of this similarity in the nonlinearity
between the model simulation and the data, an inspec-
tion of the model and the simulation results may pro-
vide insight to the underlying mechanism. During the
incubation time, when the transfected genes are being
transcribed and translated to their respective proteins,
complexes will be formed continuously. When MITF is
added, the PIAS3-MITF complex will form. The seques-
tering of PIAS3 is not only making it unavailable for
STAT3 inhibition, but also rescues PIAS3 from degrada-
tion. In the case where the smaller amount of MITF was
added, these two effects would have cancelled each
other out, while in the case where the greater amount
of MITF was added, all PIAS3 would be sequestered,
resulting in a saturated rescuing effect.
In experiment #26, a comparison was performed
between MITF wild type and a mutant that was tran-
scriptionally active, but unable to bind PIAS3. Tran-
scriptional activity was measured by rtPCR on the
mRNA of MITF and STAT3 target genes at 30 minutes
and at 4 hours after activation. When the cells were
transfected with wild type MITF, elevated transcriptional
activity was observed for both transcription factors after
activation. However, when the cells were transfected
with the MITF mutant, neither MITF nor STAT3 dis-
played elevated transcriptional activity (Figure 7A). The
model was able to mimic the change in transcriptional
activity of MITF in reaction to activation for both wild
type and mutated MITF (Figure 7B), while the transcrip-
tional activity of STAT3 was not in accordance with the
experimental data. In the simulation of this experiment,
the transcriptional activity of STAT3 increased in
response to activation, regardless of MITF mutation sta-
tus (Figure 7C). In the lab experiment, this increased
transcriptional activity was only seen in the cells with
wild type MITF and not in the cells with mutated
MITF. The authors of the original paper conclude that
PIAS3, being unable to bind the mutated MITF, is
accessible for binding and thus inhibition of STAT3. In
the model simulations, there was indeed more PIAS3
Figure 5 Simulations and lab results experiment #7. A: Reprint of Figure 2B in [20] (License agreement number 2773700432120): Kinetics of
MITF and PIAS3 association in TPA-activated BL6-B16 cells. Coimmunoprecipitation (IP) of PIAS3 with MITF at defined time points in TPA-
activated BL6-B16 cells. The cells were transfected with pcDNA-MITF and pcDNAPIAS3. The blots were probed with anti-MITF antibodies and
then reprobed with anti-PIAS3 antibody. Phosphorylation states represented by the upper band are unknown, the lower band is anticipated to
represent un-phosphorylated MITF. B: Simulation of the same experiment (experiment #7 in Table 2). The temporal development of the amount
of MITF-PIAS3 complex is plotted for all phosphorylation states of MITF, as well as for the sum of the phosphorylated states (PIAS3-MITFpAll).
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available in the case with mutated MITF, which causes
the lower peak in the level of phosphorylated STAT3 in
this case (Figure 7C). However, due to MITF
degradation, similar levels of PIAS3 becomes available
also in the case of wild type MITF, leading to no differ-
ence in level of free PIAS3 to inhibit phosphorylated
Figure 6 Simulations and lab results experiments #19 - #24. A: Reprint of Figure 3B in [22] (License agreement number 2838800627526): NIH
3T3 cells were co-transfected with STAT3, PIAS3 and with different doses of MITF (wild type [WT] or S409A [MUT] (capital letter denoting the
greater dose)). Cells were triggered with IL-6/IL-6R for 6 h. B: Simulation of the same experiment (experiments 19-24 in Table 2).
Figure 7 Simulations and lab results experiment #26. A: Reprint of figure 6D and E from [22] (License agreement number 2838800627526):
Quantitative reverse transcription-PCR analysis of MITF target genes (c-Kit and TPH) and STAT3 target genes (c-Myc and VEGF) from BMMC
activated for 0.5 or 4h with SCF derived from either wild-type or MITFdi/di mice. (B and C) Simulations of the same experiment (experiment #26
in Table 2). Note that the di/di mutation blocks the activation of both MITF and STAT3 in the reprinted lab result while in the simulation STAT3
activity is not affected.
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STAT3 activity. Thus, according to our results, the pro-
posed mechanism is not a plausible explanation of the
observed data.
Discussion
The focal melanocyte regulatory module may reflect the
need for co-regulation of two transcription factors. It
seems to provide one type of solution for obtaining dif-
ferent co-regulation effects on different time scales,
from the immediate effects on the activity of one tran-
scription factor upon activation of the other, to the long
term effect of sequestering and later release. Because
this module has components working on many different
time scales, the history leading up to an event may be
determinative. This may be of importance when inter-
preting results from experiments that operate on differ-
ent time scales, such as transfection of constitutively
active kinases compared to activation of pre-existing
kinases.
The cross talk is going mostly one way
The asymmetry of the network, introduced by PIAS3
binding to activated STAT3, while most efficiently bind-
ing to non-activated MITF, yields a particular regulatory
effect. We observe that in the model, STAT3 is more
affected by the activation of MITF than MITF is affected
by the activation of STAT3. This phenomenon, which is
in accordance with earlier observations [19,20], can be
elucidated from some features of the model. In the rest-
ing cell, PIAS3 is to a larger extent bound to un-phos-
phorylated MITF and MITFp73, which are the major
phosphorylation states in the resting cell. On the other
hand, STAT3 only binds PIAS3 when activated. Thus,
even if both transcription factors are able to alter the
amount of free PIAS3, only STAT3 is affected by it:
Activated MITF does not interact with PIAS3, and is
therefore unaffected by the amount of free PIAS3.
STAT3, on the other hand, binds PIAS3 only in acti-
vated state, and the strength of the signal is therefore
highly affected by the level of free PIAS3. This is a
mechanistic explanation for the observation that STAT3
does not associate with PIAS3 that is already associated
with MITF [19].
This model cannot explain the result of experiment #26
Our results indicate that it is not possible to mimic
experiment 26 with this model. This finding contradicts
the mechanism suggested in [22] as an explanation for
the observed data. In our opinion, these observations
must either be caused by un-expected properties in the
MITF mutant, and/or by un-modelled connections in
the network. The latter is supported by the fact that the
module modelled here is an abstraction of a small part
of a vastly complex regulatory network. Mechanisms not
accounted for in the present model include regulation
of MITF [10,27,28] and upstream co-regulators in the
JAK-STAT [29] and the SRC-STAT pathways.
The sensitivity of simulation results to parameter value
perturbations
In the sensitivity analysis the model parameters were
perturbed in a range from half to double their default
value. Some of the parameters exposed negligible effect
on the simulation results under these perturbations. For
instance there are no experiments that show high sensi-
tivity to the association and dissociation constants
kMp409ass, kMp409diss. A possible explanation for this is
that the affinity of S409 phosphorylated MITF to PIAS3
is so low that PIAS3-MITFp409 is rare compared to the
other PIAS3-MITF complexes, and modest perturba-
tions of the association and dissociation constants does
not change this situation. The MITF and STAT3 pro-
duction rates (PMITF andPSTAT3) are affecting the total
amount of protein, but still none of the experiments are
particularly sensitive to these parameters. The reason
for this seems to be that the relative response measured
in the experiments is not affected much by this total
amount.
The broader context
In the skin, the major contributors to melanocyte signal-
ling are dermal fibroblasts and epidermal keratinocytes
[30,31]. For MITF, the major regulatory pathways are
thought to be the TGF-b and the POMC derivatives
ACTH and a-MSH signalling pathways [32]. The TGF-
b pathway, which is often dysregulated in melanoma
[33,34], down-regulates MITF, while the a-MSH path-
way up-regulates MITF expression [28,35,36]. The up-
regulation occurs via a-MSH binding and activation of
MC1R, which leads to cAMP/PKA activation and activa-
tion of MAPK [36,37]. Thus, the effect of the MAPK
pathway on MITF is complex, including up-regulation,
activation and tagging for degradation. For STAT3, in
addition to the IL-6 cytokine family, growth factors such
as EGF, PDGF and KITL have been reported to activate
STAT3 [38-40]. Here, KITL is of special interest in mel-
anocyte biology. In addition to being essential for mela-
nocyte development, it has recently been reported that
the hereto unidentified coupling of MC1R activation to
MAPK proceeds via MC1R-coupled KIT activation of
MAPK [41]. With a focus on developing potential thera-
pies toward melanoma, both MITF and STAT3 have
been implicated in neoplastic progression. MITF has
been classified as a bona fide context dependent onco-
gene [12]. STAT3 has been implicated in neoplastic pro-
gression with an increased contribution especially in
metastatic melanoma [42]. Strikingly, no spontaneous or
inherited mutations have been isolated [16]. Targeting
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STAT3 is, however, feasible from both upstream and
downstream elements. In addition to being a melanoma
oncogene, depletion of MITF has been reported to
induce arrest, senescence and cell death in melanoma
identifying it as a potential target for therapy [43,44].
Indeed, a PIAS3 based peptide has been developed to
target both MITF and STAT3 via a PIAS3 23-aa mimic
[21,23].
Applicability of the Model
With regards to MITF and STAT3 and their roles in
melanocyte biology, it is intriguing that a-MSH signal-
ling is somewhat equivalent to KITL signalling with the
additional activation of the cAMP/PKA axis. This leads
to an increase in MITF production and dual phosphory-
lation of both MITF and STAT3. Likewise, a-MSH sig-
nalling in melanoma predisposing MC1R RHC (red hair
colour) mutant backgrounds, which does not elevate
cAMP, would alone be equivalent to KITL signalling in
a wild type background with regards to MITF and
STAT3, the outcome being STAT3 phosphorylation and
MITF activation and subsequent depletion. With this in
mind, the emergence of MITF’s role in melanoma and
its high frequency of duplication, it seems contradictory
that MC1R mutants predispose individuals to this dis-
ease. It will be interesting to see if compensatory muta-
tions in cAMP elevating factors such as G protein-
coupled receptors (e.g. the histamine receptor H2) are
found to be necessary for progression and if so to
model the outcomes [45-47].
Special conditions like JAK-STAT3 activation duration
due to SOCS feedback inhibition versus SRC-STAT3
activation, which is not influenced by SOCS [16], may
be simulated through the model. In addition, other rele-
vant factors such as NF--B, which is also regulated by
PIAS3 binding [48], may be added by incorporating an
NF--B module. Another interesting module would, for
example, be GM-CSF/KITL or GM-CSF/a-MSH signal-
ling. GM-CSF activates MAPK, but has been reported to
inhibit KIT signalling via direct binding of CSF2RA to
KIT [49].
With this model at hand, more detailed issues in this
network can be addressed. The previously posed ques-
tion on which phosphorylation states of MITF are repre-
sented by the upper band interpreted to be
phosphorylated MITF in Western blot analysis [13,14],
is such an issue. With the ability to test different
hypothesis in simulations, both the experiment design
and the interpretation of the experimental results could
benefit.
Further work could include refinement of various
parts of the model by integrated wet-lab modelling
efforts. The three parts of the model that could benefit
the most from structural enhancement, are the
following: (i) The mapping function from the MITF
phosphorylation states to the MITF transcriptional
activity could be represented on a higher resolution
level. This is needed for the model to address quantita-
tive data with absolute values. (ii) The production
regime of MITF, PIAS3, STAT3 and RSK1 could be
represented by both transcription and translation. (iii)
The enzymatic equations could be represented by
Michaelis-Menten kinetics. All these structural changes
will introduce more state variables and model para-
meters, thus nothing would be gained by these efforts
without the generation of accurate quantitative data to
pin down both the model structure and the parameter
values.
Conclusions
In this work, we have provided a mathematical model
of the MITF-PIAS3-STAT3 network and have
mimicked a representative selection of lab experiments
that explore the features of this network. The analyses
of this model have revealed explanations to the
observed phenomena, as well as recommended reconsi-
deration of previously proposed explanations. This
model provides a framework for further investigation
of this interesting crosstalk, and can be used as a tool
for experimental design and as starting point for
further modelling efforts.
Methods
Model description
We have developed an ordinary differential equation
(ODE) model of the MITF-PIAS3-STAT3 system. The
graphical representation of the model given in Figure 2
is represented in Systems Biology Graphical Notation as
implemented in CellDesigner [50]. The ODE-model was
implemented in MATLAB (Additional file 2 -
MATLABcode.zip). In the following the model is pre-
sented in terms of the chemical reaction equations and
the ordinary differential equations. All protein amounts
represented by the state variables in the model are pre-
sented in an arbitrary unit (au).
The amount of phosphorylated ERK is represented by
a constant (a MAPK signal is represented by an altering
of this constant). This kinase is involved in two pro-
cesses; phosphorylation of RSK1 (1) and phosphoryla-
tion of MITF at S73 (2).
RSK1
[ERKp]kRp+

kRp−
RSK1p (1)
In all the equations the subscript p after the protein
denotes phosphorylated form. The phosphorylation and
de-phosphorylation rate constants are represented by
kRp+ and kRp- respectively.
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I) MITF
[ERKp]kMp73E+

kMp73−
MITFp73
II) MITFp409
[ERKp]kMp73E+

kMp73−
MITFpp
III) PIAS3 MITF
[ERKp]kMp73E+

kMp73−
PIAS3 MITFp73
IV) PIAS3 MITFp409
[ERKp]kMp73E+

kMp73−
PIAS3 MITFpp
(2)
All the equations in (2) represent ERKp catalyzed
phosphorylation of MITF at S73. Subscripts after MITF
denote phosphorylation state (un-phosphorylated, S73
phosphorylated, S409 phosphorylated and phosphory-
lated at both sites). Complexes are represented by
underscore separated protein abbreviations. Note that
the same phosphorylation (kMp73E+) and de-phosphoryla-
tion (kMp73-) rate constants are used in all four equa-
tions. In addition MITF is auto-phosphorylated at S73
governed by a separate rate constant, kMp73a+:
I) MITF
kMp73a+−−−→ MITFp73
II) MITFp409
kMp73a+−−−→ MITFpp
III) PIAS3 MITF
kMp73a+−−−→ PIAS3 MITFp73
IV) PIAS3 MITFp409
kMp73a+−−−→ PIAS3 MITFpp
(3)
Further, the phosphorylation of MITF at S409 is cata-
lyzed by the phosphorylated RSK1:
I) MITF
[RSK1p]kMp409+

kMp409−
MITFp409
II) MITFp73
[RSK1p]kMp409+

kMp409−
MITFpp
III) PIAS3 MITF
[RSK1p]kMp409+

kMp409−
PIAS3 MITFp409
IV) PIAS3 MITFp73
[RSK1p]kMp409+

kMp409−
PIAS3 MITFpp
(4)
The four different phosphorylation states have differ-
ent association and dissociation rate constants:
MITF + PIAS3
kMass
kMdiss
PIAS3 MITF (5)
MITFp73 + PIAS3
kMp73ass

kMp73diss
PIAS3 MITFp73 (6)
MITFp409 + PIAS3
kMp409ass

kMp409diss
PIAS3 MITFp409 (7)
MITFpp + PIAS3
kMppass

kMppdiss
PIAS3 MITFpp (8)
STAT3 is also binding PIAS3:
STAT3p + PIAS3
kSpass

kSpdiss
PIAS3 STAT3p (9)
And finally the phosphorylation of STAT3 is catalyzed
by phosphorylated JAK (which is represented by a con-
stant):
STAT3
[JAKp]kSp+

kSp−
STAT3p (10)
A signal propagating through the JAK-STAT3-path-
way is represented in the model simulations by an eleva-
tion of the constant representing the amount of
phosphorylated JAK.
These chemical reactions were translated into an ODE
model by anticipating simple mass action reaction
kinetics. See Table 2 for a comprehensive list of para-
meters. Equation (11), describing the dynamics of
unbound and un-phosphorylated MITF, is provided in
detail below. One differential equation for each phos-
phorylation and complex state of each protein is given.
These equations are in the same way determined from
the chemical equations and are therefore only commen-
ted when features differ.
In this model, MITF can be present in 8 different
states and is therefore represented by 8 differential
equations, each containing parts reflecting the chemical
reactions involving that particular state.
•
[MITF] = pMITF
− kMp73E+ [MITF]
[
ERKp
]− kMp73a+ [MITF]
+ kMp73−
[
MITFp73
]
− kMp409+ [MITF]
[
RSK1p
]
+ kMp409−
[
MITFp409
]
− kMass [MITF] [PIAS3] + kMdiss [PIAS3 MITF]
− γMITF [MITF]
(11)
In differential equation (11), where the rate of
change of un-phosphorylated and un-bound MITF is
described, PMITF is the production rate, kMp73E+[MITF]
[ERKp] is the rate of MITF leaving this state because it
gets phosphorylated at S73 (reaction equation (2)),
kMp73-[MITFp73] is the rate of MITF entering this state
from the S73 single phosphorylated state due to de-
phosphorylation (reaction equation (2)), kMp73a+[MITF]
is the rate of MITF leaving this state because of auto-
phosphorylation at S73 (reaction equation (3)), kMp409
+[MITF][RSK1p] is the rate of MITF leaving this state
because of phosphorylation at S409 (reaction equation
(4)), kMp409-[MITFp409] is the rate of MITF entering
this state from the S409 single phosphorylated MITF
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state because of de-phosphorylation (reaction equation
(4)), kMass[MITF][PIAS3] is the rate of MITF leaving
this state because of MITF-PIAS3 association (reaction
equation (5)) and kMdiss[PIAS3_MITF] is the rate of
MITF entering this state due to MITF-PIAS3 dissocia-
tion (reaction equation (5)). The last term gMITF
[MITF], represents the MITF degradation. The total
amount of RSK1 is kept constant, while its phosphory-
lation state is dynamically determined by equations
(12) and (13).
•
[RSK1] = −kRp+ [RSK1]
[
ERKp
]
+ kRp−
[
RSK1p
]
(12)
•[
RSK1p
]
= kRp+ [RSK1]
[
ERKp
]− kRp−
[
RSK1p
]
(13)
The dynamics of S73 phosphorylated MITF (MITFp73)
is given in equation (14)
•[
MITFp73
]
= + kMp73E
[
ERKp
]
[MITF] + kMp73a+ [MITF]
− kMp73−
[
MITFp73
]
− kMp409+
[
RSK1p
] [
MITFp73
]
+ kMp409−
[
MITFpp
]
− kMp73ass
[
MITFp73
]
[PIAS3]
+ kMp73diss
[
PIAS3 MITFp73
]
− γMITFp73R
[
MITFp73
]
(14)
Where gMITFp73 is the degradation rate that applies to
the ubiquitinated ratio R of the amount of MITFp73. In
the dynamics of S409 phosphorylated MITF,
•[
MITFp409
]
= − kMp73E+
[
ERKp
] [
MITFp409
]− kMp73a −
[
MITFp409
]
+ kMp73−
[
MITFpp
]
+ kMp409+
[
RSK1p
]
[MITF] − kMp409−
[
MITFp409
]
− kMp409ass
[
MITFp409
]
[PIAS3]
+ kMp409diss
[
PIAS3 MITFp409
]
− γMITFp409
[
MITFp409
]
(15)
simple linear degradation is applied. When MITF is
phosphorylated on both sites, the sum of the two degra-
dation rates applies:
•[
MITFpp
]
= + kMp73E
[
ERKp
] [
MITFp409
]
+ kMp73a +
[
MITFp409
]
− kMp73−
[
MITFpp
]
+ kMp409+
[
RSK1p
] [
MITFp73
]− kMp409−
[
MITFpp
]
− kMppass
[
MITFpp
]
[PIAS3] + kMppdiss
[
PIAS3 MITFpp
]
− γMITFp73R
[
MITFpp
]− γMITFp409
[
MITFpp
]
(16)
Further, these four phosphorylation states of MITF
bind PIAS3, each with their own association and disso-
ciation rate constants, yielding differential equation
(17) for PIAS3, (18) for the MITF-PIAS3-complex, (19)
for the S73 phosphorylated MITF-PIAS3-complex, (20)
for the S409 phosphorylated MITF-PIAS3-complex
and (21) for the double phosphorylated MITF-PIAS3-
complex.
•
[PIAS3] = + pPIAS3
− kMass [PIAS3] [MITF] + kMdiss [PIAS3 MITF]
− kMp73ass [PIAS3]
[
MITFp73
]
+ kMp73diss
[
PIAS3 MITFp73
]
− kMp409ass [PIAS3]
[
MITFp409
]
+ kMp409diss
[
PIAS3 MITFp409
]
− kMppass [PIAS3]
[
MITFpp
]
+ kMppdiss
[
PIAS3 MITFpp
]
− kSpass [PIAS3]
[
STAT3p
]
+ kSpdiss
[
PIAS3 STAT3p
]
− γPIAS3 [PIAS3]
(17)
PIAS3 has a linear degradation.
•
[PIAS3 MITF] = − kMp73E+
[
ERKp
]
[PIAS3 MITF]
+ kMp73−
[
PIAS3 MITFp73
]
− kMp73a+ [PIAS3 MITF]
− kMp409+
[
RSK1p
]
[PIAS3 MITF]
+ kMp409−
[
PIAS3 MITFp409
]
+ kMass [MITF] [PIAS3]
− kMdiss [PIAS3 MITF]
− γMITF + γPIAS3
10
[PIAS3 MIFTF]
(18)
•[
PIAS3 MITFp73
]
= + kMp73E+
[
ERKp
]
[PIAS3 MITF]
− kMp73−
[
PIAS3 MITFp73
]
+ kMp73a+ [PIAS3 MITF]
− kMp409+
[
RSK1p
] [
PIAS3 MITFp73
]
+ kMp409−
[
PIAS3 MITFpp
]
+ kMp73ass
[
MITFp73
]
[PIAS3]
− kMp73diss
[
PIAS3 MITFp73
]
− γMITFp73 + γPIAS3
10
R
[
PIAS3 MITFp73
]
(19)
•[
PIAS3 MITFp409
]
= − kMp73E+
[
ERKp
] [
PIAS3 MITFp409
]
+ kMp73−
[
PIAS3 MITFpp
]
− kMp73a+
[
PIAS3 MITFp409
]
+ kMp409+
[
RSK1p
]
[PIAS3 MITF]
− kMp409−
[
PIAS3 MITFp409
]
+ kMp409ass
[
MITFp409
]
[PIAS3]
− kMp409diss
[
PIAS3 MITFp409
]
− γMITFp409 + γPIAS3
10
[
PIAS3 MITFp409
]
(20)
•[
PIAS3 MITFpp
]
= + kMp73E+
[
ERKp
] [
PIAS3 MITFp409
]
− kMp73−
[
PIAS3 MITFpp
]
+ kMp73a+
[
PIAS3 MITFp409
]
+ kMp409+
[
RSK1p
] [
PIAS3 MITFp73
]
− kMp409−
[
PIAS3 MITFpp
]
+ kMppass
[
MITFpp
]
[PIAS3]
− kMppdiss
[
PIAS3 MITFpp
]
− γMITFp73R + γPIAS3
10
[
PIAS3 MITFpp
]
− γMITFp409 + γPIAS3
10
[
PIAS3 MITFpp
]
(21)
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STAT3 is binding PIAS3 while phosphorylated. The
dynamics of the PIAS3-STAT3-complex is given in
equation (22) and un-phosphorylated and phosphory-
lated STAT3 in equation (23) and (24) respectively.
•[
PIAS3 STAT3p
]
= + kSpass
[
STAT3p
]
[PIAS3]
− kSpdiss
[
PIAS3 STAT3p
]
− γSTAT3p + γPIAS3
10
[
PIAS3 STAT3p
]
(22)
To represent higher stability by proteins in complexes,
the degradation rate of the complex is set to 20% of the
mean of the degradation rates assigned to the constitut-
ing proteins in un-bound form.
•
[STAT3] = + pSTAT3
− kSp+
[
JAKp
]
[STAT3] + kSp−
[
STAT3p
]
− γSTAT3 [STAT3]
(23)
•[
STAT3p
]
= + kSp+
[
JAKp
]
[STAT3] − kSp−
[
STAT3p
]
− kSpass
[
STAT3p
]
[PIAS3] + kSpdiss
[
PIAS3 STAT3p
]
− γSTAT3
[
STAT3p
]
(24)
S73 phosphorylated MITF get ubiquitin tagged for
degradation by phosphorylated ERK. Introducing
another modification site would cause another doubling
of the number of state variables representing MITF. To
reduce complexity, we chose to represent the ubiquiti-
nation with one differential equation (25), describing the
ratio R of the total amount of S73 phosphorylated MITF
that also is ubiquitinated.
•
R = (1 − R)
[
ERKp
]
ku (i)
−
⎛
⎜⎝R −
1 − γMITFp73a
1
R
− γMITFp73a
⎞
⎟⎠ 1
a
(ii),
− (R − RA) 1
a
(iii)
(25)
Where A is defined as
A =
[
MITFp73
]
+
[
MITFpp
]
[
MITFp73
]
+
[
MITFpp
]
+
(
pMITF −
[
MITFp409
]
γMITFp409
)
a
(26)
The three parts of equation (25) correspond to the
three processes altering the ratio R: (i) The ubiquitina-
tion of un-ubiquitinated MITF, (ii) the ubiquitination
dependent degradation of ubiquitinated MITF and (iii)
the production of new un-ubiquitinated MITF. In (i),
the ubiquitination rate constant ku, denotes the rate of
change of R and thus have the unit au-1 min-1. To
derive part (ii), let R’ be the ratio R after one minute of
ubiquitin mediated degradation. Then the rate of change
due to this effect is -(R - R’) per minute, where
R′ =
RB − RBγMITFp73a
B − BγMITFp73a =
1 − γMITFp73a
1
R
− γMITFp73a (27)
and B = [MITFp73] + [MITFpp]. The term a = 1 and
has the unit minute and does not affect the calculation,
but is needed for the correct unit representation. Part
(iii) is derived in a similar way: Let R’’ be the ratio R
after one minute of MITF production. Then the rate of
change due to this effect is -(R - R’’) per minute, where
R′′ = R
([
MITFp73
]
+
[
MITFpp
])
[
MITFp73
]
+
[
MITFpp
]
+
(
pMITF −
[
MITFp409
]
γMITFp409
)
a
. (28)
MITF activity
The readouts of the model are the amounts of the dif-
ferent phosphorylation and complex states of the pro-
teins involved. To be able to view this model in the
light of available experimental results, these levels have
to be interpreted in a way comparable to the lab-gener-
ated data. The transcriptional activity of MITF and
STAT3 is measured either as luciferase activity of a
transfected reporter gene or as mRNA-levels of down-
stream genes.
We thus devised a function f([MITF],[MITFp73],
[MITFp409],[MITFpp]) to map the amounts of the differ-
ent phosphorylation states of MITF to a downstream
transcriptional activity. The production of any gene pro-
duct can be modelled by a function f(S1,S2,....,SN), where
Sj is the concentration of the N species affecting the
transcription and translation of the particular gene pro-
duct. This function can be described at various levels of
precision from the basic principles of chemical kinetics,
via Michaelis-Menten enzymatic kinetics to low order
polynomials that function as an ansatz for the actual
molecular mechanisms. The function that maps from
the amounts of the MITF phosphorylation states to pro-
duction rate of downstream genes will probably differ
between target genes on a higher resolution level. How-
ever, for the resolution level of the current effort, one
mapping function is sufficient. We have approximated
the MITF activity by a sum of first order polynomials,
which in effect is a weighted sum:
f = A0 + AM [MITF] + AM73
[
MITFp73
]
+ AM409
[
MITFp409
]
+ AMpp
[
MITFpp
] (29)
Values for the transcriptional activity of different
MITF mutants are given in [14]. From these we have
calculated the factors to be AM = -0.11, AM73 = 0.44,
AM409 = 0.11 and AMpp = 0.56. This simple representa-
tion of MITF transcriptional activity is able to take
negative values, which does not make sense biologically;
therefore, A0 is set to the relative high arbitrary value
Thingnes et al. BMC Systems Biology 2012, 6:11
http://www.biomedcentral.com/1752-0509/6/11
Page 13 of 19
10, which is sufficiently high to avoid negative MITF
activity in this study.
Parameterizing the model
While this model contains a large number of para-
meters, we can make at least a reasonable order of mag-
nitude estimate for most of them from empirical
biological data. In the experiments used for model
development and parameter fitting, neither implicit nor
explicit absolute protein amounts have been provided.
The cells are either transfected, activated or both, and
thus the input protein amounts and perturbations will
by this fact be qualitative. The results are presented as
qualitative protein or complex amounts (Western blot)
or transcriptional activity for MITF and PIAS3 (mea-
sured by luciferase assays or PCR-measurements of tar-
get genes mRNA levels). These results are quantified
relative to a control, but not in absolute terms.
An estimate for the degradation rates of PIAS3 and
STAT3 is calculated directly from the protein stability
index (PSI) as presented in [25] (gSTAT3 = 0.002 and
gPIAS3 = 0.008). The PSI derived degradation rate for
MITF is 0.008, but MITF is known to be relatively
stable in un-phosphorylated form while ERK mediated
phosphorylation on S73 also tags MITF for proteasome
mediated degradation [13,14]. To match degradation
time series data [13,14] MITF was assigned a low degra-
dation rate in the un-phosphorylated state, gMITF =
0.0012, and relatively high degradation rate when phos-
phorylated on S409 (regardless of phosphorylation status
on S73), gMITFp73 = 0.01. The proportion of MITF phos-
phorylated on S73 (regardless of phosphorylation status
on S409) is degraded only when ubiquitinated (and then
with a rather high degradation rate, gMITFp73 = 0.02).
The ubiquitination rate constant is adjusted to ku =
0.0001 to yield degradation in accordance with data
[13,14]. When the proteins are in complex, they are
thought to be more stable than as free molecules. As an
approximation the degradation rates of all complexes
were set to 20% of the average of the degradation rate
of the two components.
The production rates for MITF, PIAS3 and STAT3
are complex functions of the concentration of a large
number of substances, of which none are involved in
this model. Therefore these production rates are repre-
sented here by constants whose values are relative to
the corresponding degradation rates determined by the
steady state levels of each of the three proteins. It is
important for the proper function of this module that
these three proteins are present at approximately equi-
molar levels. The values are therefore set to pMITF = 1,
pPLAS3 = 1.262 and pSTAT3 = 0.211 to meet this criterion.
This yields a steady state amount of approximately 100
(au). The level of phosphorylated ERK in the resting cell
is set to ERKp = 10 and is elevated to approximately
1000 whenever a MAPK signal is simulated. The total
amount of RSK1 is set to 500 of which the phosphoryla-
tion is determined dynamically (equation (12) and (13)).
The phosphorylation speed for RSK1 is found in [14],
and the phosphorylation and de-phosphorylation rate
constants calculated to kRp+ = 0.0004 and kRp- = 0.04,
respectively. The Western blot analysis of MITF pre-
sented in [13] and [14] has one band interpreted as un-
phosphorylated MITF and one band interpreted as
phosphorylated MITF. No interpretation is provided on
which phosphorylation states this latter band may repre-
sent. By interpreting this band as the sum of all phos-
phorylated MITF, we have adjusted the phosphorylation
rate constants of MITF to make the model behaviour fit
the experimental data. The rate constants are set to
kMp73E+ = 0.00015, kMp73- = 0.03, kMp73a+ = 0.025,
kMp409+ = 0.0001 and kMp409- = 0.04. With no direct
measurements of the STAT3 phosphorylation rate, we
assigned the same values to the STAT3 phosphoryla-
tion/de-phosphorylation rate constants as we did for
RSK1: kSp+ = 0.0002 and kSp- = 0.04. The constant
representing phosphorylated JAK is set to 10 in the un-
activated state and approximately 1000 in the activated
state.
With no direct measurements of the MITF-PIAS3 and
STAT3-PIAS3 association and dissociation rate con-
stants, they were inferred from qualitative results and
assumptions. We anticipated that this process is faster
than the phosphorylation process, which means that
both association and dissociation rate constants should
be relatively high. MITF has lower affinity to PIAS3
when phosphorylated at S409 and higher affinity when
phosphorylated at S73, compared to un-phosphorylated
MITF [20]. The double phosphorylated MITF exhibits
an intermediate affinity comparable to that of un-phos-
phorylated MITF [20]. When the MITF-PIAS3 associa-
tion/dissociation rate constants were adjusted so that
the model emulated the results from [20], they were
assigned the following values: kMiss = 0.01, kMdiss = 1,
kMp73ass = 0.03, kMp73diss = 0.5, kMp409ass = 0.0001,
kMp409diss = 1, kMppass = 0.01 and kMppdss = 1. The
STAT3-PIAS3 association/dissociation rate constants
were adjusted in the same way to data from [22] and
are assigned the values kSpass = 0.005 and kSpass = 0.2.
Formalizing the experiments
We extracted a set of representative experiments from
four relevant publications [14,19,20,22] (Table 2). The
numbering in the table provided a unique ID for each
experiment, and was used throughout the article. The
perturbations of the cells that were reported in the pub-
lished experiments, like transfection of mutated genes or
receptor activation, were assigned digital counterparts in
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the model through alterations of the input values, start-
ing values, or some of the parameters. In the following,
these details, as well as the criteria used for the sensitiv-
ity analysis, are given for each of the experiments.
Experiment # 1 is a simulation of the experiment pre-
sented in [14] Figure 5B. Here, the authors use kinase
assays to investigate the temporal development of ERK
and RSK1 kinase activity after stimulation of melanoma
cells. The stimulation was simulated by elevation of the
amount of phosphorylated ERK to 1000 from the default
value of 10. The success criterion used in the sensitivity
analysis was that the phosphorylated RSK1 level should
reach 90% of its maximum between 3 and 10 minutes
after activation.
Experiment #2 simulates the pre-stimulation distribu-
tion among the MITF phosphorylation states in the
experiments presented in [14], Figure 1 and 2. To emu-
late the growing cell culture the level of phosphorylated
ERK was elevated from the default value of 10 to the
intermediate level of 80. Steady state values were found
for the state variables and the total amount of phos-
phorylated and un-phosphorylated MITF was compared.
The success criterion used in the sensitivity analysis was
that both categories should be between 25% and 75% of
the total amount.
Experiment #3 is also based on [14], Figure 1 and 2.
Here, the phosphorylation state of MITF after 30 min-
utes of activation is considered. The cell stimulation is
simulated by elevation of the levels of phosphorylated
ERK and JAK from the default value of 10 to 1000. The
success criterion used in the sensitivity analysis was that
more than 80% of the MITF is phosphorylated after 30
minutes.
Experiment #4 is also based on [14], Figure 1 and 2.
Here, the degradation profile is considered. The cell sti-
mulation is simulated by elevation of the levels of phos-
phorylated ERK and JAK from the default value of 10 to
950. The success criterion used in the sensitivity analysis
is that less than 50% of the MITF is degraded after 1 h
and at least two thirds are degraded after 5 h.
Experiment #5 is a simulation of the experiment pre-
sented in [19], Figure 6. Here, the authors have trans-
fected MITF, a MITF reporter gene, and different
amounts of PIAS3 into NIH 3T3 fibroblasts (endogen-
ously not expressing MITF). To mimic MITF transfec-
tion, the MITF production rate is increased from 1 to
18. To mimic the four different amounts of PIAS3
transfection, the PIAS3 production rate was increased
from 0.211 to 0.5, 1, 2 and 4. The model was simulated
for 2880 minutes (2 days) for each perturbation and the
resulting MITF activity was compared for the four
PIAS3 levels. The success criterion used in the sensitiv-
ity analysis was that MITF activity should be monotoni-
cally decreasing with increasing PIAS3 and that the
MITF activity at the highest PIAS3 amount should be
less than the half that of the lowest PIAS3 amount.
In experiments #6 and #7, we have mimicked the
experiments presented in [20], Figure 2. Here the
authors have investigated the association between MITF
and PIAS3 in BL6-B16 cells before and after 10 and 30
minutes of activation with c-kit ligand. In experiment #6
only GFP-PIAS3 was transfected, while in experiment
#7, the cells were transfected with both MITF and
PIAS3. In experiment #6, activation is performed by
increase of the levels of phosphorylated ERK and JAK
from 10 to 500 and 50, respectively. In experiment #7,
transfection was simulated by elevation of the MITF
production rate from 1 to 10 and the PIAS3 production
rate from 1.262 to 10 and simulated for 2880 minutes (2
days). Thereafter, activation was simulated by increase of
the amount of phosphorylated ERK and JAK from 10 to
1200 and 250, respectively. The success criterion used
for the sensitivity analysis in both experiments was that
the total amount of MITF-PIAS3-complex should be
higher after 10 minutes of stimulation compared to
before stimulation and that the amount of complex
should be lower after 30 minutes of stimulation than
after 10 minutes.
Experiment #8 simulated the experiment from [20],
Figure 3A, left. The authors co-transfected NIH 3T3
cells using MITF, with a constitutively active RSK1 plas-
mid and with a reporter gene to read MITF activity. To
simulate transfection of MITF, the MITF production
rate was elevated from 1 to 7. The amount of RSK1 is
not dynamically determined in the model, and thus the
transfection of this product is approximated with an ele-
vation of the static amount from 500 to 5000. The
manipulated model was simulated for 2880 minutes (2
days), and the MITF activities with and without RSK1
were compared. The success criteria used in the sensi-
tivity analysis was that the two cases should not differ
more than twofold.
Experiments #9 to #12 represent simulations of the
experiment presented in [20] Figure 3B. Here, the
authors transfected NIH 3T3 cells with MITF or the
MITF-S409A mutant, with constitutively active RSK1
and with a reporter gene to monitor MITF transcrip-
tional activity. To simulate the transfection of MITF, the
MITF production rate was elevated from 1 to 7. To
simulate the transfection of PIAS3, the PIAS3 produc-
tion rate was elevated from 1.262 to 4. The amount of
RSK1 is not dynamically determined in the model, and
thus the transfection of this product is approximated
with an elevation of the static amount from 500 to
5000. The activation level was elevated from 10 to 20 to
emulate the activity in growing cells. After simulation
for 2880 minutes (2 days), the MITF activities, with and
without PIAS3 were compared for each of the four
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experiments. For each experiment the manipulations
were as follows: without RSK1, with wild-type MITF
(experiment #9), with RSK1 and wild-type MITF
(experiment #10), without RSK1, with mutant MITF
(experiment #10) and with RSK1, with mutant MITF
(experiment #11). The success criterion used in the sen-
sitivity analysis was for each experiment: Experiment #9:
MITF activity in the case with PIAS3 is less than 42%
and greater than 2% of that without PIAS3. Experiment
#10: MITF activity in the case of PIAS3 is less than 84%
and greater than 44% of that without PIAS3. Experiment
#11: MITF activity in the case of PIAS3 is less than 55%
and greater than 15% of that without PIAS3. Experiment
#12: MITF activity in the case of PIAS3 is less than 50%
and greater than 10% of that without PIAS3.
Experiment #13 to #16 are simulations of the experi-
ment presented in [20] Figure 6. In this experiment the
authors investigate the inhibition of transcriptional
activity of S/D mutants of MITF by PIAS3. This is
achieved by transfection of wild-type MITF (experiment
#13), MITF-S73D (experiment #14), MITF-S409D
(experiment # 15) or MITF-S73/409D (experiment #16)
and PIAS3 and a reporter gene into NIH 3T3 cells. We
simulated the MITF transfection by elevation of the
MITF production rate from 1 to 1.5, and the PIAS3
transfection was simulated by elevation of the PIAS3
production rate from 1.262 to 4.5. Here we have also set
all MITF levels to zero before starting the simulation,
since NIH 3T3 fibroblasts do not express endogenous
MITF. To simulate MITF-S73D mutation we have set
the MITF S73 de-phosphorylation rate constant to zero
while the MITF S73 auto-phosphorylation rate constant
is elevated from 0.025 to 5. To simulate MITF-S409D
mutation, the RSK1 phosphorylation rate constant is
elevated form 0.0004 to 0.04, the RSK1 de-phosphoryla-
tion rate constant is decreased from 0.04 to 0.004, the
MITF S409 phosphorylation rate constant is elevated
from 0.0001 to 0.01 and the MITF S409 de-phosphory-
lation rate constant is set to zero. The model was simu-
lated for 2880 minutes (2 days) and the MITF
transcriptional activity with PIAS3 was compared with
the case without PIAS3 for wild-type MITF, and for
each mutation form. The success criterion used for the
sensitivity analysis was for each experiment: Experiment
#13: MITF activity in the case of PIAS3 is less than 70%
and greater than 30% of that without PIAS3. Experiment
#14: MITF activity in the case of PIAS3 is less than 50%
and greater than 10% of that without PIAS3. Experiment
#15: MITF activity in the case of PIAS3 is less than
115% and greater than 75% of that without PIAS3.
Experiment #16: MITF activity in the case of PIAS3 is
less than 85% and greater than 45% of that without
PIAS3.
Experiments #17 and #18 are simulations of the
experiment presented in [22] Figure 3A. Here, the
authors investigate PIAS3-STAT3 association in
response to stimulation of NIH 3T3 cells transfected
with STAT3, PIAS3 and MITF or the MITF S409A-
mutant. The transfection is simulated by elevation of
the MITF production rate from 1 to 10, the PIAS3 pro-
duction rate from 1.262 to 10 and the STAT3 produc-
tion rate from 0.211 to 10. The MITF S409A mutation
was simulated by setting the MITF S409 phosphoryla-
tion rate constant to zero. The activation was simulated
by elevation of the amount of phosphorylated ERK and
JAK from 10 to 1000. In experiment #17, wild-type
MITF, PIAS3 and STAT3 were all transfected and simu-
lated for 2880 minutes (2 days), thereafter simulated for
15 more minutes with and without stimulation. The
amount of PIAS3-STAT3-complex was compared. The
success criterion used in the sensitivity analysis was that
the amount of PIAS3-STAT3-complex should be at
least 25% higher with stimulation compared to the case
without stimulation. In experiment #18, S409A MITF,
PIAS3 and STAT3 were transfected and simulated for
2880 minutes (2 days), and thereafter simulated for 15
more minutes with or without stimulation. The amount
of PIAS3-STAT3-complex was compared with the sti-
mulated case in experiment #17. The success criterion
used in the sensitivity analysis was that the amount of
PIAS3-STAT3-complex in the stimulated case in experi-
ment #17 should be at least 25% higher than the
amount of PIAS3-STAT3-complex in any of the two
cases in #18.
Experiments #19 to #24 are simulations of the experi-
ment presented in [22] Figure 3B. Here, the authors
have investigated STAT3 transcriptional activity as a
response to activation, transfection of PIAS3, and trans-
fection of various amounts of wild-type and S409A
mutated MITF in NIH T3T cells. The activation was
simulated by elevation of the amounts of phosphorylated
ERK and JAK from 10 to 1000. The transfections of
PIAS3, STAT3 and the two different MITF amounts
were simulated by elevation of the PIAS3 production
rate from 1.262 to 7, the STAT3 production rate from
0.262 to 5, and the MITF production rate from 1 to 10
or 50, respectively. The S409A mutation was simulated
by setting the MITF phosphorylation rate constant to
zero. The model was run for 2880 minutes to simulate
the incubation and then for 360 minutes to simulate the
activation. The background luciferase activity of STAT3
was determined by elevation of the STAT3 production
rate and running a model simulation for 3240 (2880
+360) minutes. The amount of phosphorylated STAT3
in the end was interpreted as an estimate for the lucifer-
ase activity of STAT3 without activation and without
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PIAS3 or MITF. For experiments #19 to #24, the
amount of phosphorylated STAT3 was compared to this
background level. In experiment #19, the cells were
transfected with STAT3 and activated. The success cri-
terion used in the sensitivity analysis was the level of
phosphorylated STAT3 between 10 and 20 times the
background level. In experiment #20, the cells were
transfected with STAT3 and PIAS3 and activated. The
success criterion used in the sensitivity analysis was the
level of phosphorylated STAT3 between 2.67 and 5.33
times the background level. In experiment #21 the cells
were transfected with STAT3, PIAS3 and the smaller
amount of MITF and activated. The success criterion
used in the sensitivity analysis was the level of phos-
phorylated STAT3 between 2.67 and 5.33 times the
background level. In experiment #22 the cells were
transfected with STAT3, PIAS3 and the larger amount
of MITF and activated. The success criterion used in
the sensitivity analysis was the level of phosphorylated
STAT3 between 6.67 and 13.33 times the background
level. In experiment #23 the cells were transfected with
STAT3, PIAS3 and the smaller amount of S409A
mutated MITF and activated. The success criterion used
in the sensitivity analysis was the level of phosphorylated
STAT3 between 5.67 and 11.33 times the background
level. In experiment #24 the cells were transfected with
STAT3, PIAS3 and the larger amount of S409A mutated
MITF. The success criterion used in the sensitivity ana-
lysis was the level of phosphorylated STAT3 between 10
and 20 times the background level.
Experiment #25 simulated the experiment presented
in [22] Figure 4B. Here, the authors have investigated
MITF transcriptional activity in response to transfection
of PIAS3, STAT3-Y705F mutant and a constitutively
active STAT3 mutant (STAT3-C) in NIH 3T3 cells. The
transfections were simulated by elevation of the produc-
tion rate of MITF from 1 to 2, PIAS3 from 1.262 to 2
and STAT3 from 0.211 to 20. The NIH 3T3 cells were
simulated by decreasing the starting values of all MITF
and PIAS3 states to 1 and in simulations where MITF
or PIAS3 were not transfected; their production rate
were set to zero. The STAT3-Y705F mutant was simu-
lated by setting the STAT3 phosphorylation rate con-
stant to zero. STAT3-C was simulated by increase the
STAT3 phosphorylation rate constant from 0.0002 to
0.02 and setting the de-phosphorylation rate constant to
zero. Six different simulations were performed and the
MITF transcriptional activity was compared: (i) Cells
transfected with STAT3-Y705F, (ii) cells transfected
with STAT3-C, (iii) cells transfected with MITF and
STAT3-Y705F, (iv) cells transfected with MITF and
STAT3-C, (v) cells transfected with MITF, PIAS3 and
STAT3-Y705F and (vi) cells transfected with MITF,
PIAS3 and STAT3-Y705F. The success criterion used in
the sensitivity analysis was that the MITF transcriptional
activity from simulation (i) should be between 50% and
150% of the MITF activity form (ii) and the MITF activ-
ity from (iii) should be between 80% and 120% of the
MITF activity from (iv) and the MITF activity from (v)
should be between 12.5% and 100% of the MITF activity
from (vi) and the MITF activity from (i) should be less
than the MITF activity from (iii) and the MITF activity
from (iii) should be greater than 200% of the MITF
activity from (v).
Experiment #26 simulates the experiment presented in
[22] Figure 6D and 6E. Here, the authors use mRNA
levels of MITF and STAT3 target genes to investigate
MITF and STAT3 transcriptional activity after stimula-
tion of mast cells derived from wild type or mutant
mice. The MITF protein from the mutated mice lacks
its ability to bind PIAS3. The activation is simulated by
elevation of the amounts of phosphorylated ERK and
JAK from 10 to 1000. The mutation is simulated by set-
ting all four MITF-PIAS3 association rate constants to
zero. The success criterion used in the sensitivity analy-
sis was for cells from wild type mice: MITF activity after
30 minutes should be more than twice the MITF activity
without stimulation, STAT3 activity at 4 hours should
be more than twice the STAT3 activity without stimula-
tion and for cells from mutated mice: MITF activity at
30 minutes and at 4 hours should be less than twice the
MITF activity without stimulation and STAT3 activity
at 30 minutes and 4 hours should be less than twice the
STAT3 activity without stimulation.
Experiments #27 and #28 are simulations of the
experiments presented in [22] Figure 7C and 7D. In
experiment #27 the authors have investigated the
STAT3 transcriptional activity in response to transfec-
tion of wild type MITF and a MITF mutant emulating
MITF phosphorylated at S409. In experiment #28 the
authors have investigated MITF transcriptional activity
in response to transfection of constitutively active
STAT3 (STAT3-C). The transfections were simulated by
elevation of the STAT3 production rate from 0.211 to 5
and the MITF production rate from 1 to 5. The MITF
mutant was simulated by setting the MITF-S409 phos-
phorylation rate constant to 5 and the MITF-S409 de-
phosphorylation rate constant to zero. The STAT3-C
mutant was simulated by increasing the STAT3 phos-
phorylation rate by 25 times and setting the de-phos-
phorylation rate to zero. The model was simulated for
2880 minutes without and with each of the three trans-
fections. The success criterion used in the sensitivity
analysis was for experiment #27 that the STAT3 activity
had increased when the cells were transfected with
MITF or the MITF mutant compared to without trans-
fection and that the increase was higher when cells were
transfected with wild type MITF compared to mutated
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MITF. The success criterion used in the sensitivity ana-
lysis for experiment #28 was MITF activity increased by
at least 10%.
Sensitivity analysis
The ability of the model to mimic the experiments
described above was tested for values of the core para-
meters in the multidimensional neighbourhood of the
default values. Each parameter was sampled from a dis-
tribution being uniform on the logarithmic scale, with a
sampling area reaching from one half to double the
default value. For each set of values of the core para-
meters, the experiments were simulated and the result
(success or failure) was recorded for each experiment.
This procedure was repeated 106 times resulting in 106
parameter sets, each with a corresponding result vector
recording success or failure for each experiment.
In order to study the sensitivity of each experiment i’s
success rate to variation in a parameter j, we sorted all
parameter sets according to parameter j and divided
them into 100 bins of 10000 parameter sets each. We
used fi , the o verall success rate of experiment i (see
Table 2, column 6) and f ki,j , the success rate in bin k to
computed the sensitivity measure si,j =
100∑
k=1
| f ki,j − fi | . In
order to remove clearly insensitive parameters, we set to
zero all si, j that did not exceed the maximum value
observed under 10000 permutations of the parameter
values.
Additional material
Additional file 1: A zip-file containing temporal plots for all
variables for all simulated experiments with default parameters. The
figures are in jpg-format.
Additional file 2: A zip-file containing an MATLAB implementation
of the model and scripts used to carry out this study. In addition to
the MATLAB scripts, a readme file is provided with instructions on how
to get the model running.
Acknowledgements
This study was supported by The National Programme for Research in
Functional Genomics (FUGE) in the Research Council of Norway
Author details
1Centre for Integrative Genetics (CIGENE), Department of Mathematical
Sciences and Technology, Norwegian University of Life Sciences, 1430 Ås,
Norway. 2Centre for Integrative Genetics (CIGENE), Department of Animal
and Aquacultural Sciences, Norwegian University of Life Sciences, 1430 Ås,
Norway. 3Department of Tumor Biology, Institute for Cancer Research, The
Norwegian Radium Hospital, Montebello, PO Box 4950 Nydalen, 0424 Oslo,
Norway. 4Institute of Medical Informatics, The Norwegian Radium Hospital,
Montebello, PO Box 4950 Nydalen, 0424 Oslo, Norway. 5Institute of
Informatics, The Faculty of Mathematics and Natural Sciences, University of
Oslo, Postboks 1080, Blindern, 0316 OSLO, Norway.
Authors’ contributions
JT, SWO and EH conceived the paper. JT designed the model, generated the
parameter set, performed the programming and analysis of the model, and
drafted the manuscript. TJL, ABG and SWO participated in model definition
and revisions. TJL and EH contributed with knowledge on the biological
scope, and with parameter estimation. ABG and JT performed the sensitivity
analysis. All authors revised the manuscript. All authors read and approved
the final manuscript.
Received: 23 October 2011 Accepted: 8 February 2012
Published: 8 February 2012
References
1. Alaluf S, Barrett K, Blount M, Carter N: Ethnic variation in tyrosinase and
TYRP1 expression in photoexposed and photoprotected human skin.
Pigment Cell Res 2003, 16(1):35-42.
2. Burns TF, Rook A: Rook’s textbook of dermatology. Malden, Mass.; Oxford:
Blackwell Science;, 7 2004.
3. Fitzpatrick TB: Dermatology in general medicine: textbook and atlas.
McGraw-Hill;, 3 1987.
4. Rosdahl I, Rorsman H: An estimate of the melanocyte mass in humans. J
Invest Dermatol 1983, 81(3):278-281.
5. Tadokoro T, Yamaguchi Y, Batzer J, Coelho SG, Zmudzka BZ, Miller SA,
Wolber R, Beer JZ, Hearing VJ: Mechanisms of skin tanning in different
racial/ethnic groups in response to ultraviolet radiation. J Invest Dermatol
2005, 124(6):1326-1332.
6. Whiteman DC, Parsons PG, Green AC: Determinants of melanocyte density
in adult human skin. Arch Dermatol Res 1999, 291(9):511-516.
7. Spatz A, Batist G, Eggermont AM: The biology behind prognostic factors
of cutaneous melanoma. Curr Opin Oncol 2010, 22(3):163-168.
8. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE,
Nishimura EK, Golub TR, Fisher DE: Critical role of CDK2 for melanoma
growth linked to its melanocyte-specific transcriptional regulation by
MITF. Cancer Cell 2004, 6(6):565-576.
9. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L,
Goding CR: Mitf cooperates with Rb1 and activates p21Cip1 expression
to regulate cell cycle progression. Nature 2005, 433(7027):764-769.
10. Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the
microphthalmia transcription factor network. Annu Rev Genet 2004,
38:365-411.
11. Watanabe A, Takeda K, Ploplis B, Tachibana M: Epistatic relationship
between Waardenburg syndrome genes MITF and PAX3. Nat Genet 1998,
18(3):283-286.
12. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S,
Beroukhim R, Milner DA, Granter SR, Du J, et al: Integrative genomic
analyses identify MITF as a lineage survival oncogene amplified in
malignant melanoma. Nature 2005, 436(7047):117-122.
13. Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL Jr: MiTF links Erk1/2
kinase and p21 CIP1/WAF1 activation after UVC radiation in normal
human melanocytes and melanoma cells. Mol Cancer 2010, 9:214.
14. Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER,
Fisher DZ, Fisher DE: c-Kit triggers dual phosphorylations, which couple
activation and degradation of the essential melanocyte factor Mi. Genes
Dev 2000, 14(3):301-312.
15. Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth,
differentiation and survival signals relayed through the IL-6 family of
cytokine receptors. Oncogene 2000, 19(21):2548-2556.
16. Herrmann A, Vogt M, Monnigmann M, Clahsen T, Sommer U, Haan S,
Poli V, Heinrich PC, Muller-Newen G: Nucleocytoplasmic shuttling of
persistently activated STAT3. J Cell Sci 2007, 120(Pt 18):3249-3261.
17. Pranada AL, Metz S, Herrmann A, Heinrich PC, Muller-Newen G: Real time
analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem 2004,
279(15):15114-15123.
18. Sehgal PB: Paradigm shifts in the cell biology of STAT signaling. Semin
Cell Dev Biol 2008, 19(4):329-340.
19. Levy C, Nechushtan H, Razin E: A new role for the STAT3 inhibitor, PIAS3:
a repressor of microphthalmia transcription factor. J Biol Chem 2002,
277(3):1962-1966.
20. Levy C, Sonnenblick A, Razin E: Role played by microphthalmia
transcription factor phosphorylation and its Zip domain in its
transcriptional inhibition by PIAS3. Mol Cell Biol 2003, 23(24):9073-9080.
Thingnes et al. BMC Systems Biology 2012, 6:11
http://www.biomedcentral.com/1752-0509/6/11
Page 18 of 19
21. Levy C, Lee YN, Nechushtan H, Schueler-Furman O, Sonnenblick A,
Hacohen S, Razin E: Identifying a common molecular mechanism for
inhibition of MITF and STAT3 by PIAS3. Blood 2006, 107(7):2839-2845.
22. Sonnenblick A, Levy C, Razin E: Interplay between MITF, PIAS3, and STAT3
in mast cells and melanocytes. Mol Cell Biol 2004, 24(24):10584-10592.
23. Yagil Z, Kay G, Nechushtan H, Razin E: A specific epitope of protein
inhibitor of activated STAT3 is responsible for the induction of apoptosis
in rat transformed mast cells. J Immunol 2009, 182(4):2168-2175.
24. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K: Specific inhibition of
Stat3 signal transduction by PIAS3. Science 1997, 278(5344):1803-1805.
25. Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ: Global protein stability
profiling in mammalian cells. Science 2008, 322(5903):918-923.
26. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE: MAP kinase links
the transcription factor Microphthalmia to c-Kit signalling in
melanocytes. Nature 1998, 391(6664):298-301.
27. Wan P, Hu Y, He L: Regulation of melanocyte pivotal transcription factor
MITF by some other transcription factors. Mol Cell Biochem 2011.
28. Yang G, Li Y, Nishimura EK, Xin H, Zhou A, Guo Y, Dong L, Denning MF,
Nickoloff BJ, Cui R: Inhibition of PAX3 by TGF-beta modulates melanocyte
viability. Mol Cell 2008, 32(4):554-563.
29. Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T,
Kharbanda S, Kufe D: MUC1-C oncoprotein promotes STAT3 activation in
an autoinductive regulatory loop. Sci Signal 2011, 4(160):ra9.
30. Hirobe T: How are proliferation and differentiation of melanocytes
regulated? Pigment Cell Melanoma Res 2011, 24(3):462-478.
31. Yamaguchi Y, Hearing VJ: Physiological factors that regulate skin
pigmentation. Biofactors 2009, 35(2):193-199.
32. Loeken MR: How TGF-beta and PAX3 regulate suntanning. Pigment Cell
Melanoma Res 2009, 22(2):146-147.
33. Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metastasis Rev
1991, 10(2):89-101.
34. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M:
Constitutive expression of multiple growth factor genes by melanoma
cells but not normal melanocytes. J Invest Dermatol 1991, 97(1):20-26.
35. Moustakas A: TGF-beta targets PAX3 to control melanocyte
differentiation. Dev Cell 2008, 15(6):797-799.
36. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA: Binding of
melanotropic hormones to the melanocortin receptor MC1R on human
melanocytes stimulates proliferation and melanogenesis. Endocrinology
1996, 137(5):1627-1633.
37. Herraiz C, Jimenez-Cervantes C, Zanna P, Garcia-Borron JC: Melanocortin 1
receptor mutations impact differentially on signalling to the cAMP and
the ERK mitogen-activated protein kinase pathways. FEBS Lett 2009,
583(19):3269-3274.
38. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE: ErbB receptor-
induced activation of stat transcription factors is mediated by Src
tyrosine kinases. J Biol Chem 1999, 274(24):17209-17218.
39. Sachsenmaier C, Sadowski HB, Cooper JA: STAT activation by the PDGF
receptor requires juxtamembrane phosphorylation sites but not Src
tyrosine kinase activation. Oncogene 1999, 18(24):3583-3592.
40. Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P:
Mechanisms of STAT protein activation by oncogenic KIT mutants in
neoplastic mast cells. J Biol Chem 2010, 286(8):5956-5966.
41. Herraiz C, Journe F, Abdel-Malek Z, Ghanem G, Jimenez-Cervantes C, Garcia-
Borron JC: Signaling from the human melanocortin 1 receptor to ERK1
and ERK2 mitogen-activated protein kinases involves transactivation of
cKIT. Mol Endocrinol 2010, 25(1):138-156.
42. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF,
Hersey P: Mcl-1, Bcl-XL and Stat3 expression are associated with
progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease
during progression of melanoma. Mod Pathol 2007, 20(4):416-426.
43. Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A,
Hofman V, Hofman P, Ponzio G, et al: Microphthalmia-Associated
Transcription Factor Controls the DNA Damage Response and a
Lineage-Specific Senescence Program in Melanomas. Cancer Res 2010.
44. Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, Le Gras S, Cormont M,
Ballotti R, Bertolotto C, et al: Essential role of microphthalmia transcription
factor for DNA replication, mitosis and genomic stability in melanoma.
Oncogene 2011, 30(20):2319-2332.
45. Kim NH, Lee AY: Histamine effect on melanocyte proliferation and
vitiliginous keratinocyte survival. Exp Dermatol 2010, 19(12):1073-1079.
46. Yoshida M, Hirotsu S, Nakahara M, Uchiwa H, Tomita Y: Histamine is
involved in ultraviolet B-induced pigmentation of guinea pig skin. J
Invest Dermatol 2002, 118(2):255-260.
47. Yoshida M, Takahashi Y, Inoue S: Histamine induces melanogenesis and
morphologic changes by protein kinase A activation via H2 receptors in
human normal melanocytes. J Invest Dermatol 2000, 114(2):334-342.
48. Jang HD, Yoon K, Shin YJ, Kim J, Lee SY: PIAS3 suppresses NF-kappaB-
mediated transcription by interacting with the p65/RelA subunit. J Biol
Chem 2004, 279(23):24873-24880.
49. Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-
macrophage colony-stimulating factor receptor interacts with c-Kit and
inhibits c-Kit signaling. J Biol Chem 2006, 281(31):22421-22426.
50. Funahashi A, Morohashi M, Kitano H, Tanimura N: CellDesigner: a process
diagram editor for gene-regulatory and biochemical networks. BIOSILICO
2003, 1(5):159-162.
51. Le Novere N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E,
Wegner K, Aladjem MI, Wimalaratne SM, et al: The Systems Biology
Graphical Notation. Nat Biotechnol 2009, 27(8):735-741.
doi:10.1186/1752-0509-6-11
Cite this article as: Thingnes et al.: Towards a quantitative
understanding of the MITF-PIAS3-STAT3 connection. BMC Systems Biology
2012 6:11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thingnes et al. BMC Systems Biology 2012, 6:11
http://www.biomedcentral.com/1752-0509/6/11
Page 19 of 19
